The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy, is pleased to announce the publication of a new clinical practice guideline (CPG) focused on immunotherapy for the treatment of gastrointestinal cancer.
MILWAUKEE, June 12, 2023 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy, is pleased to announce the publication of a new clinical practice guideline (CPG) focused on immunotherapy for the treatment of gastrointestinal cancer.
The manuscript, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer", was published in the Journal for ImmunoTherapy of Cancer (JITC), SITC's peer-reviewed, open-access online journal.
"Immunotherapy has transformed the standard of care for many gastrointestinal cancers, improving treatment responses and offering some patients prolonged survival," said Ronan Kelly, MB BCh, MBA, co-chair of the SITC Gastrointestinal Cancer Immunotherapy Guideline Expert Panel. "The efficacy of immunotherapy in gastrointestinal cancers, however, is very much dependent on a comlex interplay of biomarker status, histology, and the tumor site of origin."
Although ICI therapy has improved outcomes for many patients with GI cancer, biomarker-negative disease remains unresponsive to standard immunotherapy combinations, with diseases such as microsatellite stable colon cancer remaining a leading cause of cancer-related death worldwide.
"Immunotherapy has made a tremendous positive impact on the treatment of patients with MSI-H/dMMR colorectal cancers in the metastatic setting, with exciting developments emerging in the neoadjuvant setting," said Dung Le, MD, co-chair of the SITC Gastrointestinal Cancer Immunotherapy Guideline Expert Panel.
Using ICIs in gastrointestinal cancer requires a highly nuanced consideration of biomarker positivity, histology, and the anatomical site of cancer origin. To support clinicians in shared decision-making with their patients, the Gastrointestinal Cancer Immunotherapy Guideline Expert Panel developed evidence- and consensus-based recommendations on topics including selection of appropriate immunotherapeutic regimens, biomarkers, and patient education and quality of life considerations.
Abridged versions of the guideline highlighting key information from the publication will be available in SITC's CPG Mobile App, along with interactive tools and tables to support clinical decision-making.
"The SITC clinical practice guidelines offer practical guidance on the use of immunotherapy based on a critical review of available data and years of collective experience from SITC's distinguished expert panelists," said SITC President Leisha Emens, MD, PhD. "The SITC CPG Mobile App delivers high-yield immunotherapy recommendations, algorithms, and interactive tools in a convenient easy-to-use format for busy clinicians."
In addition to the guideline, SITC will be also offering free live webinars and on-demand modules hosted on the SITC website focusing on topics within this guideline and providing attendees the opportunity to ask questions of expert faculty:
- Practical Management Pearls – SITC CPG Webinar
- Case Studies – SITC CPG Webinar
The dates and times of the webinars will be available soon on this web page.
Click here to view past SITC Cancer Immunotherapy Guidelines webinars available free and on-demand.
About SITC's Guidelines
The SITC Cancer Immunotherapy Guidelines Program is a collection of clinical practice guidelines (CPGs) developed by multidisciplinary panels of experts who draw from practical experience as well as evidence in the published literature and clinical trial data to provide recommendations for clinicians on how on how and when to use immunotherapy to help improve outcomes for patients with cancer. SITC's guidelines provide recommendations on topics including selection of appropriate immunotherapy treatments, toxicity management, biomarkers, and considerations for patient quality of life. SITC's expanding catalogue of CPGs spans disease-state specific guidelines for several solid tumors, hematologic malignancies, and toxicity-specific guidelines to assist clinicians with the management of immune-related adverse events. You may access the entire series of CPGs in the Journal for ImmunoTherapy of Cancer (JITC), the society's open access, peer-reviewed online journal, or in the CPG Mobile App.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings, and other resources at sitcancer.org and follow us on Twitter, LinkedIn and YouTube.
About JITC
The Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.bmj.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on Twitter @jitcancer.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414.276.2456, [email protected]
SOURCE Society for Immunotherapy of Cancer
Share this article